Список литературы

1. Rodeghiero F., Stasi R., Gernsheimer T., Michel M., Provan D., Arnold D.M., et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from international working group. Blood. 2009; 113(11): 2386 - 93. doi: 10.1182/blood-2008-07-162503.

2. Cines D.B., Cuker A., Semple J.W. Pathogenesis of immune thrombocytopenia. PresseMed.2014; 43(4 Pt2): e49 - 59. doi: 10.1016/j.lpm.2014.01.010

3. Меликян А.Л., Пустовая Е.И., Калинина М.В., Володичева Е.М., Капорская Т.С., Ильясов Р.К., Бабаева Т.Н., Беккер О.М., Богова В.С., Зотина Е.Н., Зотова И.И., Контиевский И.Н., Пяткова О.А., Соколова И.С., Федорова Н.А., Шестопалова И.А., Колошейнова Т.И., Егорова Е.К., Куликов С.М. Эпидемиологические характеристики первичной иммунной тромбоцитопении у взрослого населения в Российской Федерации. Клиническая онкогематология. Фундаментальные исследования и клиническая практика. 2017; N 4 (10): 558 - 559.

4. Provan D., Stasi R., Newland A.S., Blanchette V.S., Bolton-Maggs P., Bussel J.B., et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood. 2010; 115(2): 168 - 86. doi: 10.1182/blood-2009-06-225565.

5. Neunert C., Lim W., Crowther M., Cohen A., Solberg L.Jr., Crowther M.A. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood. 2011; 117(16): 4190 - 207. doi: 10.1182/blood-2010-08-302984.

6. Масчан А.А., Румянцев А.Г., Ковалева Л.Г., Афанасьев Б.В., Поспелова Т.И., Зарицкий А.Ю. и др. Рекомендации Российского совета экспертов по диагностике и лечению больных первичной иммунной тромбоцитопенией. Онкогематология. 2010; 3: 36 - 45.

7. Ковалева Л.Г., Пустовая Е.И., Сафонова Т.И. Идиопатическая тромбоцитопеническая пурпура (ИТП) взрослых. Первичная иммунная тромбоцитопения (ИТП) взрослых. Болезнь Верльгофа. М.: Нью Мун; 2014.

8. Меликян А.Л., Пустовая Е.И., Егорова Е.К., Калинина М.В., Колошейнова Т.И., Суборцева И.Н., Гилязитдинова Е.А., Двирнык В.Н. Дифференциальная диагностика тромбоцитопений. Онкогематология. 2017; 12(1): 78 - 87.

9. Provan D., Arnold D., Bussel J.B., Chong B.H., Cooper N., Gernsheimer T., Ghanima W., et.al. Updated international consensus report on the investigation and management of primary immune thrombocytopenia. Blood advances. 2019; 3(22): 3780 - 3808. doi: 10.1182/bloodadvances-2019000812.

10. Kurokawa T., Ohkohchi N. Ohkohchi Platelets in liver disease, cancer and regeneration. World J Gastroenterol. 2017 May 14; 23(18): 3228 - 3239. PMID: 28566882 doi: 10.3748/wjg.v23.i18.3228

11. Protocole national de diagnostic et de soins (PNDS) Purpura thrombopenique immunologiquede l'enfant et de l'adulte. Haute - Mai 2017, 73 p.

12. Carneiro-Sampaio M., Moraes-Vasconcelos D., Kokron C.M., Jacob C.M., Toledo-Barros M., Dorna M.B., et al. Primary immunodeficiency diseases in different age groups: a report on 1,008 cases from a single Brazilian reference center. J. Clin. Immunol. 2013; 33(4): 716 - 24.

13. Michel M., Cooper N., Jean C., Frissora C., Bussel B. Does Helicobacter pylori initiate or perpetuate immune thrombocytopenic purpura? Blood, 2004, 103(3): 890 - 896. Doi: 10.11.1182/blood-2003-03-0900.

14. Liu Y., Chen S., Sun Y., Lin O., Liao X., Zhang J., Luo J., Ouian H., Shi G. Clinical characteristics of immune thrombocytopenia associated with autoimmune disease: A retrospective study. 2016 Dec; 95(50): e5565.

15. Matzdorff A., Eberl W., Kiefel V., T., Meyer O., Ostermann H., Pabinger-Fasching I., Rummel M.J., B. Immunthrombozytopenie (ITP). Onkopedia leitlinien - 2018, 46 p.

16. Wei Y., Ji X.B., Wang Y.W., Wang J.X., Yang E.O., Wang Z.C., Sang Y.O., et.al. High-dose dexamethasone vs prednisone for treatment of adult immune thrombocytopenia: a prospective multicenter randomized trial. Blood. 2016 Jan 21; 127(3): 296 - 302; quiz 370. doi: 10.1182/blood-2015-07-659656.

17. Kovaleva L., Apte S., Damodar S., et al; investigators of the Flebogamma DIF in ITP Study Group. Safety and efficacy of a 10% intravenous immunoglobulin preparation in patients with immune thrombocytopenic purpura: results of two international, multicenter studies. Immunotherapy. 2016; 8(12): 1371 - 1381.

18. Stasi R. How to approach thrombocytopenia. Hematology Am Soc HematolEduc Programm 2012; 2012: 191 - 7. Doi:10.1182/ash education-2012.1.191.

19. Von dem Borne A.E., Vos J.J., Pegels J.G., Thomas L.L., van der Lelie. High dose intravenous methylprednisolone or high dose intravenous gammaglobulin for autoimmune thrombocytopenia. Br Med J (Clin Res Ed). 1988; 296(6617): 249 - 250.

20. Ghanima W., Godeau B., Cines D.B., Bussel J.B. How I treat immune thrombocytopenia: the choice between splenectomy or a medical therapy as a second-line treatment. Blood. 2012 Aug 2; 120(5): 960 - 9. doi: 10.1182/blood-2011-12-309153.

21. Frenzel W., Wietek S., Svae T.E., Debes A., Svorc D. Tolerability and safety of Octagam (IVIG): a post-authorization safety analysis of four non-interventional phase IV trials. Int J Clin Pharmacol Ther. 2016; 54(11): 847 - 855.

22. Robak T., Salama A., Kovaleva L., et al; International Privigen in ITP Study Group. Efficacy and safety of Privigen, a novel liquid intravenous immunoglobulin formulation, in adolescent and adult patients with chronic immune thrombocytopenic purpura. Hematology. 2009; 14(4): 227 - 236.

23. Robak T., Mainau C., Pyringer B., et al. Efficacy and safety of a new intravenous immunoglobulin 10% formulation (octagam 10%) in patients with immune thrombocytopenia. Hematology. 2010; 15(5): 351 - 359.

24. Cines D.B., McMillan R. Management of adult idiopathic thrombocytopenic purpura. Annu.Rev.Med. 2005; 56: 425 - 42. doi:10.1146/annurev.med.56.082103.104644

25. Neunert C., Terrell D.R., Arnold D.M., Buchanan G., Cines D.B., Coopr N., et al. American Society of Hematology 2019 guidelinesfor immune thrombocytopenia. Blood Adv. 2019; 3(23): 3829 - 3867. doi: 10.1182/bloodadvances.2019000966.

26. Carr A.C., Maggini S. Review Vitamin C and Immune Function. Nutrients 2017, 9, 1211; doi:10.3390/nu9111211

27. Тимирханова Г.А., Абдуллина Г.М., Кулагина И.Г. Витамин C: классические представления и новые факты о механизмах биологического действия. Вятский медицинский вестник. 2007, N 4. Актуальные вопросы современной биохимии. 3: 158 - 161.

28. Козярин И.П., Липкан Г.Н., Мвахно А.П. Жгучая, но полезная. Крапива двудомная - лекарственное и пищевое растение (обзор литературы). Гiгiена населених мiсць. 2013; 62: 246 - 250 УДК:615.322:582.635.5:613.26

29. Данишян К.И., Соболева О.А., Галстян Г.М., Зверева А.В., Соркина О.М. Лапароскопическая спленэктомия при иммунной тромбоцитопенической пурпуре у беременных. Терапевтический архив, 2016; 7: 109 - 113.

30. Карагуюлян С.Р., Данишян К.И., Шутов С.А., Силаев М.А. Технические сложности выполнения спленэктомии при заболеваниях системы крови. Клиническая онкогематология. 2017; 10(1): 101 - 7. doi:10.21320/2500-2139-2017-10-1101-107.

31. Vianelli N., Palandri F., Polverelli N., Stasi R., Joelsson J., Johansson E., Ruggeri M., Zaja F. et al. Splenectomy as a curative treatment for immune thrombocytopenia: a retrospective analysis of 233 patients with a minimum follow up of 10 years. Haematologica. 2013; 98(6): 875 - 880.

32. Vianelli N., Galli M., de Vivo A., Intermesoliti T., Giannini B., Mazzucconi M.G., et.al, Efficacy and safety of splenectomy in immune thrombocytopenic purpura: long-term results of 402 cases. Haematologica. 2005; 90(1): 72 - 77.

33. Park Y.H., Yi H.G., Kim C.S., et al; Gyeonggi/Incheon Branch, The Korean Society of Hematology. Clinical outcome and predictive factors in the response to splenectomy in elderly patients with primary immune thrombocytopenia: a multicenter retrospective study. Acta Haematol. 2016; 135(3): 162 - 171.

34. Tada K., Ohta M., Saga K., et al. Long-term outcomes of laparoscopic versus open splenectomy for immune thrombocytopenia. Surg Today. 2018; 48(2): 180 - 185.

35. Chater C., Terriou L., Duhamel A., et al. Reemergence of splenectomy for ITP second-line treatment? Ann Surg. 2016; 264(5): 772 - 777.

36. Vecchio R., Marchese S., Intagliata E., Swehli E., Ferla F., Cacciola E. Long-term results after splenectomy in adult idiopathic thrombocytopenic purpura: comparison between open and laparoscopic procedures. J Laparoendosc Adv Surg Tech A. 2013; 23(3): 192 - 198.

37. Boyle S., White R.H., Brunson A., Wun T. Splenectomy and the incidence of venous thromboembolism and sepsis in patients with immune thrombocytopenia. Blood. 2013; 121(23): 4782 - 4790.

38. Thai L.H., Mahevas M, Roudot-Thoraval F., et al. Long-term complications of splenectomy in adult immune thrombocytopenia. Medicine (Baltimore). 2016; 95(48): e5098.

39. Choi Y.U., Dominguez E.P., Sherman V., Sweeney J.F. Laparoscopic accessory splenectomy for recurrent idiopathic thrombocytopenic purpura. JSLS. 2008; 12(3): 314 - 317.

40. Kuter D.J., Bussel J.B., Newland A., Baker R.I., Lyons R.M., Wasser J., et al. Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia safety and efficasy. Br.J. Haematol. 2013; 161(3): 411 - 23. doi: 10.1111/bjh.12260.

41. Newland A., Godeau B., Priego V., et al. Remission and platelet responses with romiplostim in primary immune thrombocytopenia: final results from a phase 2 study. BrJ Haematol. 2016; 172(2): 262 - 273.

42. Marshall A.L., Scarpone R., De Greef M., Bird R., Kuter D.J. Remissions after long-term use of romiplostim for immune thrombocytopenia. Haematologica. 2016; 101(12): e476 - e478.

43. Cines D.B., Wasser J., Rodeghiero F., et al. Safety and efficacy of romiplostim in splenectomized and nonsplenectomized patients with primary immune thrombocytopenia. Haematologica. 2017; 102(8): 1342 - 1351.

44. Saleh M.N., Bussel J.B., Cheng G., Meyer O., Bailey C.K., Arning M., Brainsky A.; EXTEND Study Group. Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study. Blood. 2013 Jan 17; 121(3): 537 - 45. doi: 10.1182/blood-2012-04-425512. Epub 2012 Nov 20.

45. Bussel J.B., Saleh M.N., Vasey S.Y., Mayer B., Arning M., Stone N.L. Repeated short-term use of eltrombopagin patients with chronic immune thrombocytopenia (ITP). BrJ Haematol. 2013 Feb; 160(4): 538 - 46. doi: 10.1111/bjh.12169.

46. Cheng G., Saleh M.N., Marcher C., Vasey S., Mater B., Aivado M., et.al. Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study. Lancet. 2011; 377(9763): 393 - 402. doi: 10.1016/S0140-6736(10)60959-2.

47. Al-Samkari H., Kuter D.J. An alternative intermittent eltrombopag dosing protocol for the treatment of chronic immune thrombocytopenia. Br J Clin Pharmacol. 2018; 84(11): 2673 - 2677.

48. Gonzalez-Lopez T.J., Fernandez-Fuertes F., Hernandez-Rivas J.A., et al. Efficacy and safety of eltrombopag in persistent and newly diagnosed ITP in clinical practice. Int J Hematol. 2017; 106(4): 508 - 516.

49. Tomiyama Y., Miyakawa Y., Okamoto S., et al. A lower starting dose of eltrombopag is efficacious in Japanese patients with previously treated chronic immune thrombocytopenia. J Thromb Haemost. 2012: 10(5): 799 - 806.

50. Gonzalez-Lopez T.J., Alvarez-Roman M.T., Pascual C., et al. Eltrombopag safety and efficacy for primary chronic immune thrombocytopenia in clinical practice. Eur J Haematol. 2016; 97(3): 297 - 302.

51. Gonzales-Porras J.R., Mingot-Castellano M.E., Andrade M.M., Alonso R., Caparros I., et al. Use of eltrombopag after romiplostim in primary immune thrombocytopenia. BrJ Hematology, 2015, 169, 111 - 116. Doi 10.1111/bjh.13266

52. Khellaf M., Viallard J.F., Hamidou M., Cheze S., Roudot-Thoraval F., Lefrere F., et. al. A retrospective pilot evaluation of switching thrombopoietic receptor-agonists in immune thrombocytopenia. Haematologica 2013; 98(6): 881 - 7. Doi: 10.3324/haematol.2012.074633.

53. Kuter D.J., Macahilig C., Grotzinger K.M., et al. Treatment patterns and clinical outcomes in patients with chronic immune thrombocytopenia (ITP) switched to eltrombopag or romiplostim. Int J Hematol. 2015; 101(3): 255 - 263.

54. Puavilai T. et al. Treatment efficacy for adult persistent immune thrombocytopenia: a systematic review and network meta-analysis //British journal of haematology. - 2020. - T. 188. - N. 3. - С. 450 - 459.

55. Cervinek L., Cerna O., Caniga M., et al. Efficacy of rituximab in primary immune thrombocytopenia: an analysis of adult pretreated patients from everyday hematological practice. Int J Hematol. 2012; 96(5): 594 - 599. doi: 10.1007/s12185-012-1206-7.

56. Hai Zhou et al. A multicenter randomized open-label study of rituximab plus rhTPOvs rituximab in corticosteroid-resistant or relapsed ITP. Blood. 2015; 125(10): 1541 - 7. doi: 10.1182/blood-2014-06-581868.

57. Khellaf M., Charles-Nelson A., Fain O., et al. Safety and efficacy of rituximab in adult immune thrombocytopenia: results from a prospective registry including 248 patients. Blood. 2014; 124(22): 3228 - 3236. doi: 10.1182/blood-2014-06-582346.

58. Arnold D.M., Heddle N.M., Carruthers J. et al. A pilot randomized trial of adjuvant rituximab or placebo for nonsplenectomisedpatients with immune thrombocytopenia. Blood. 2012; 119: 1356 - 1362

59. Ghanima W., Khelif A., Waage A. et al. Rituximab as second-line treatment for adult immune thrombocytopenia (the RITP trial): a multicenter, randomised, double blind, placebo-controlled trial. Lancet 2015; 385: 1653 - 1661 dx.doi.org/10.1016/S0140-6736(14)61495-1

60. Chugh S., Darvish-Kazem S., Lim W., et al. Rituximab plus standard of care for treatment of primary immune thrombocytopenia: a systematic review and meta-analysis. Lancet Haematol. 2015; 2(2): e75 - e81.

61. Patel V.L., Mahevas M., Lee S.Y., et al. Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia. Blood. 2012; 119(25): 5989 - 5995.

62. Marangon M., Vianelli N., Palandri F., et al. Rituximab in immune thrombocytopenia: gender, age, and response as predictors of long-term response. Eur J Haematol. 2017; 98(4): 371 - 377.

63. Pasa S., Altintas A., Cil T., Danis R., Ayyildiz O. The efficacy of rituximab in patients with splenectomized refractory chronic idiopathic thrombocythopenic purpura. J Thromb Thrombolysis. 2009; 27(3): 329 - 333.

64. Mahevas M., Ebbo M., Audia S., et al. Efficacy and safety of rituximab given at 1,000 mg on days 1 and 15 compared to the standard regimen to treat adult immune thrombocytopenia. Am J Hematol. 2013; 88(10): 858 - 861.

65. Zaja F., Vianelli N., Volpetti S., et al. Low-dose rituximab in adult patients with primary immune thrombocytopenia. Eur J Hematol. 2010; 85(4): 329 - 334.

66. Arnold D.M., Nazi I., Santos A., et al. Combination immunosuppressant therapy for patients with chronic refractory immune thrombocytopenic purpura. Blood. 2010; 115(1): 29 - 31.

67. Gomez-Almaguer D., Tarin-Arzaga L., Moreno-Jaime B., et al. High response rate to low-dose rituximab plus high-dose dexamethasone as frontline therapy in adult patients with primary immune thrombocytopenia. Eur J Hematol. 2013; 90(6): 494 - 500.

68. Gudbrandsdottir S., Birgens H.S., Frederiksen H., et al. Rituximab and dexamethasone vs dexamethasone monotherapy in newly diagnosed patients with primary immune thrombocytopenia. Blood. 2013; 121(11): 1976 - 1981.

69. Chapin J., Lee C.S., Zhang H., Zehnder J.L., Bussel J.B. Gender and duration of disease differentiate responses to rituximab-dexamethasone therapy in adults with immune thrombocytopenia. Am J Hematol. 2016; 91(9): 907 - 911.

70. Bussel J.B., Lee C.S., Seery C., et al. Rituximab and three dexamethasone cycles provide responses similar to splenectomy in women and those with immune thrombocytopenia of less than two years duration. Haematologica. 2014; 99(7): 1264 - 1271.

71. Абузарова Г.Р. et al. Обезболивание взрослых и детей при оказании медицинской помощи. Методические рекомендации. ФГБОУ ВО РНИМУ им. Н.И. Пирогова Минздрава России, 2016 г., 94 с.

72. Piel-Julian M.L., Mahesvas M., Germain J., et al; CARMEN investigators group. Risk factors for bleeding, including platelet count threshold, in newly diagnosed immune thrombocytopenia adults. J Thromb Haemost. 2018; 16(9): 1830 - 1842. doi: 10.1111/jth.14227.

73. Gernsheimer T., James A.H., Stasi R. How I treat thrombocytopenia in pregnancy. Blood. 2013 Jan 3; 121(1): 38 - 47. doi: 10.1182/blood-2012-08-448944.

74. Васильев С.А., Виноградов В.Л., Мазуров А.В., Маркова М.Л. Тромбоцитопении. Акушерство, гинекология и репродукция. 2014; N 2: с. 112 - 125.

75. Sukenik-Halevy R., Ellis M.H., Fejgin M.D. Management of immune thrombocytopenic purpura in pregnancy. Obstet Gynecol Surv. 2008 Mar; 63(3): 182 - 8. doi: 10.1097/OGX.0b013e318164013c.

76. George J.N., Nester C., McIntosh J. Syndromes of thrombotic microangiopathy associated with pregnancy. Hematology Am Soc Hem Education Program, 2015, Dec 5, 644 - 8

77. Fakhouri F. Pregnancy-related thrombotic microangiopathies: clues from complement biology, Transfusion and ApheresSci, 2016, 54, p 199 - 202

78. Кирсанова Т.В., Виноградова М.А., Федорова Т.А., Имитаторы тяжелой преэклампсии HELLP синдрома: различные виды тромботической микроангиопатии, ассоциированной с беременностью. Акушерство и гинекология, 2016, 12, с 5 - 14